Showing posts with label unethical. Show all posts
Showing posts with label unethical. Show all posts

Friday, 28 March 2008

THE ENDS JUSTIFY THE MEANS, NO MATTER HOW DESPICABLE THESE MEANS ARE

In a response to Dr. Michael Siegel's comment in his blog about the failure of a scientist to disclose the funding she received from tobacco industry interests for her research on CT screening for lung cancer, Mr. Bill Godshall, Executive Director of Smokefree Pennsylvania, unwillingly (or perhaps even willingly) exhibited the dogmatic ideology that characterizes the tobacco control movement: The end justifies any and all means.

His comment was not only devoid of any scientific merit and human compassion, but it eloquently illustrated that any means, ethical or unethical, moral or immoral, must be employed towards coercing smokers into quitting.


After reading such a comment from an executive director of a public health organization, it makes it abundantly clear that scrutiny for truthfulness and scientific accuracy of anything spewed by the tobacco control dogmatists, is an absolute necessity.

The comment (color emphasis ours) :

While shocked that Dr. Claudia Henschke's research didn't disclose Liggett's funding, and that she is now claiming public health advocates knew about the funding source, CT scans have the potential to increase the dismal 15% five-year survival rate for lung cancer, and may prove to be the single most effective smoking cessation tool.

Mike wrote:

"having 90% of your patients with nodules worrying unnecessarily for 3 months hardly seems acceptable to me."

I cannot think of a more effective incentive (than worrying about having early stage lung cancer) to encourage smokers to quit smoking.

Mike also wrote:

"Ninety percent of the time, the test is wrong. That's usually viewed as being unacceptable for a screening test."Since false positive tests could be even more beneficial for the health of the smoker (when worrying about a false positive convinces the smoker to quit) than true positive tests (whose resulting treatment is not going to save the lives of many or most lung cancer patients), CT lung cancer screenings of smokers is likely to even more effective as a smoking cessation aid than as a lung cancer screening tool.

A caveat is that false positive CT lung cancer tests in ex-smokers (who comprise slightly greater than half of new lung cancer cases) is likely to cause unnecessary worrying, without providing any benefit. Thus, perhaps somewhat different CT lung screening guidelines should be considered for current smokers and for ex-smokers.

Bill Godshall 03.28.08 - 12:09 pm #

Monday, 3 March 2008

CONFLICTS OF INTEREST IN THE SCIENTIFIC AND MEDICAL PROFESSIONS

The British Medical Journal published two articles debating the issue of conflict of interest that corporate funding causes in the scientific and medical profession.

The ‘’No’’ side to the question: Has the hunt for conflicts of interest gone too far? No, is defended by Kirby Lee, assistant professor of clinical pharmacy who declares no competing interests and the ‘’Yes’’ side to the same question: Has the hunt for conflicts of interest gone too far? Yes, is defended by Thomas P Stossel, professor, who declared the following competing interests: TPS is on the boards of directors and owns stock options in ZymeQuest and Critical Biologics Corporations, and his employer has licensed intellectual property to these companies, which may result in his receiving milestone payments, royalties and in the stock options having financial value. He receives fees for speaking to corporations and other organisations on the topic of conflict of interest. He has served on scientific advisory boards for Biogen, Dyax, and Merck.

You may want to read both sides of the debate and vote on the poll (during the time it’s available) on either of the pages. You may also wish to post a comment on the comments to the article section.

As far as our views on this, from our past articles and our critical analysis on the pharmaceutical industry, you may have correctly guessed that we think that the hunt on conflicts of interest, hasn't gone far enough.



Thursday, 28 February 2008

DAVID VS. GOLIATH

The pharmaceutical giants are under attack. Never have we seen such a persistent global offensive against this industry, as we have in the last few weeks. It gives us hope that public awareness is growing and that Big Pharma will finally be held accountable for a number of their immoral and unethical tactics motivated strictly by financial interests.

All private companies are motivated by profits and we citizens have developed natural defenses and critical skills to appraise most products that are offered to us. However, because we naively believe that public health would never allow corporate interests to play with our health, we have a tendency not to question the medical and scientific community and that’s where we are fooled.

When the health and economies of societies are directly affected by unscrupulous tactics, that’s when governments have to step in to protect the public from such wrong-doing. Unfortunately the lobbying powers of the legal drug pushers, coupled with a number of corrupted politicians throughout the world, leave us citizens looking like David vs. Goliath. Our elected officials should be held unmercifully accountable for any free passes they are granting Big Pharma. Our physical, psychological and economic health, depend on it.

Following is the latest offensive against Big Pharma:

Drug giants warned: Tell the truth on medicines

After antidepressant treatments are discredited, fears grow that other products may be ineffective

By Jeremy Laurance, Health Editor
Wednesday, 27 February 2008

The pharmaceutical industry came under assault from senior figures in medical research yesterday over its practice of withholding information to protect profits, exposing patients to drugs which could be useless or harmful.

Experts criticised the stranglehold exerted by multinational companies over clinical trials, which has led to biased results, under-reporting of negative findings and selective publication driven by the market, which was worth £10.1bn in the UK in 2006, amounting to 11 per cent of total NHS costs.

The latest attack was triggered yesterday by an analysis of published and unpublished trials of modern antidepressants, including Prozac and Seroxat, showing they offer no clinically significant improvement over placebos (dummy pills) in most patients. But doctors said patients on the drugs should not stop taking them without consulting their GPs.

It was the first time researchers – from the UK, Canada and the US – had successfully used freedom of information legislation to obtain all the data presented to regulators when the companies applied to license their drugs. In some cases it had not been made public for 20 years.

Over the past two decades the drugs, known as selective serotonin re-uptake inhibitors (SSRIs), have been among the biggest selling of all time, earning billions of pounds for their makers. Yesterday's finding suggests that the money may have been misspent. Drug companies are required by law to provide all data on a drug, published and unpublished, to the regulatory authorities when applying for a licence. But this requirement does not apply to the National Institute for Health and Clinical Excellence (Nice), which assesses cost effectiveness and recommends which drugs should be used by the NHS.

Peter Littlejohns, the clinical and public health director of Nice, said: "The regulatory authorities have access to everything. Obviously we have access to the published data and we do ask the industry for unpublished data, but it is up to the companies whether to deliver it or not. We have no power to demand it. The issue is that it relies on the good will of the industry."

Professor Mike Clarke, the director of the UK Cochrane Centre, an international collaboration between researchers in 100 countries which has published more than 3,000 systematic reviews of published trials to establish best medical practice, said lack of co-operation from the drug industry was damaging medical care.

"When we ask for details of a trial the company might tell us nothing. We have even less power than Nice. Researchers trying to make sense of trials for decision-makers need to have access to this data. If we have only got access to half of the data, when we see evidence that a drug works we don't know whether to believe it or not.

"It makes us doubtful – that's the big worry. The companies are in the business of making profits – but they are also in the business of providing safe, effective health care."

Legislation to compel the drug industry to publish its results was included in Labour's manifesto at the 2005 election and last month the Commons Health Select Committee demanded that Nice be given unfettered access to all clinical trial results.

Yesterday, the Government said it had been told that compelling the industry to publish trial data would not be allowed and it was instead pursuing a voluntary approach, developing a "searchable register" of all trials that have taken place in the UK and pressing the EU to make its own confidential register public.

A spokesman for the Department of Health said: "The Government has consistently supported open access to information about research when the findings could affect decisions about treatment or health outcomes. We planned to support the principle of mandatory registration of clinical trials in the UK, but legal advice stated this would be illegal under EU law." A World Health Organisation working group is examining how to improve reporting of clinical trials and is expected to announce a consultation shortly.

The pharmaceutical industry was unrepentant about its strategy yesterday. Richard Tiner, the head of medicines at the Association of the British Pharmaceutical Industries, said: "The regulatory authorities have access to all the data – absolutely everything. Nice is not a regulatory authority – it is making decisions on whether medicines should be available on the NHS... There is no reason why the companies would restrict access – it depends what they are asked for. The industry is very much more transparent than it was 10 years ago."

GlaxoSmithKline, maker of Seroxat, said yesterday it "fully endorsed public disclosure of all clinical trial results" and had published all data relating to Seroxat on its website "regardless of study outcome".

The antidepressant debate

Paul Bough, 41: 'You name it, I've tried it: none of them worked'
"The findings of this latest report don't surprise me in the slightest. In fact, they confirm what I already knew.

"I've been a depressive for most of my life, and all of my adult life. After the umpteenth failed suicide attempt seven years ago my doctor said I should try taking antidepressant drugs. You name it, I've tried it. Diazepam, Citalopram, Prozac, Seroxat, Atenolol [a beta-blocker], Efexor: none worked. They turned me into a zombie, totally incapable of motivation or movement and forced to vegetate on a sofa.

"I'd say to anyone on these drugs, you're better off going cold turkey. Talk to people, have therapy, be sociable: but don't rely on these little happy pills. Having tried the lot, I'm coming off – and staying off."

Sylvia Genge, 59: 'Without these drugs I would lose hope altogether'

"The findings go against several decades of experience. I have suffered three major traumas in my life – my father leaving home when I was 11, my husband having an affair, and now an unpleasant divorce – and I'm convinced these drugs helped me survive them. I've been close to suicide myself, but now, in my 60th year, I'm feeling positive and able to survive all the terrifying experiences each day throws at me. I take 20mg of Fluoxetine each day, and it makes me feel I can cope. I simply don't buy the idea that it's just a placebo – but then I suppose the point is even if it were I wouldn't care. These drugs are my crutch and my comfort; without them I would lose hope altogether. I'm staying on."

Monday, 21 January 2008

ETHICS GUIDELINES FOR CLINICAL TRIALS TO BE REVISED

Having been shut off from getting any information on clinical trials with nicotine replacement therapy on pregnant women on the grounds that it was ‘’confidential information’’, we experienced firsthand how unaccountable the pharmaceutical industry has become in the last two decades. The conclusion we have come to following our in-depth research on the issue, concurs with the statement in the CMAJ article below -- "It's been said that (Big Pharma's reputation) is worse than the tobacco industry at the moment".

It is with great enthusiasm that we look forward to the new ethical guidelines that might mark the beginning of some accountability of the healthcare industry and the numerous tentacles it has developed over the years.

Ethics guidelines for clinical trials to be revised

Peter O'Neil
Paris, France

In the wake of ongoing international furor over drug trial horror stories and in hopes of restoring its own fading influence on the global stage, the World Medical Association is proposing to again update its cornerstone statement of ethical principles regarding human experimentation.

To that end, the France-based ethics guardian is seeking input on proposed revisions to the Declaration of Helsinki, which was first developed in 1964 as the medical profession's code of conduct governing the ethics of human research. The Declaration's 11 paragraphs have since been expanded to 32 over the course of 5 revisions, the most recent of which occurred in 2000.

The latest review comes at a time when the pharmaceutical industry's reputation for testing the safety of drugs prior to mass marketing has been in steady free-fall, says Dr. John Williams, the former ethics director of the Canadian Medical Association (1991–2003) and the World Medical Association (2003–2006), who is coordinating the revision process. "Since 2000 there have been so many scandals that have been unleashed that the need for ethical principles, and regulations and laws as well — first of all to be formulated, and second to be applied — is stronger than ever."

Association President Dr. Jon Snaedal of Iceland acknowledges that the proposed amendments are being driven by a desire to re-establish the Declaration's relevance in a world where national and international bodies, like the World Health Organization, have their own far more detailed standards and regulations on ethical trial conduct.

The Association describes most of the proposed Declaration changes as "minor" adjustments, including new wording to stress the rights of trial participants, a call for greater representation of under-represented groups such as children and pregnant women (to ensure companies provide adequate recommended dosages to these groups), and an assertion that "professional" patients who engage in numerous trials for financial reasons be discouraged. The proposals also echo a chorus of international calls for a public database where details of clinical trials would be registered.

More controversial is a decision by the Association to again wade into the fray surrounding the use of "placebos" in clinical trials. Such use prompted the Association to weigh-in with Declaration revisions in 2000, after public outcry erupted over a trial involving HIV-positive women in the developing world. It gave one-half of all participants the drug azidothymidine to determine if a shorter-course treatment would be as, or almost as, effective as the proven longer-course treatment, and the other half a placebo, even though an existing treatment was available. The women in the control group, who came to the trial with the singular hope of sparing their babies the ravages of their own disease, essentially lost a lottery when they ended up getting only a placebo.

Some ethicists defended the trial by arguing that the women would likely have received no treatment had the trial not been conducted. But others recoiled at the notion of a doctor or clinician giving a placebo to a participant that would increase the chances her child could die a horrible death.

That hardened opposition to the Declaration within industry, regulatory bodies and amidst some academic circles, all of whom argued that such restrictions on placebo use were impractical and would seriously impair research. The Association added "a note of clarification" in 2002 which included the statement that placebo use may be acceptable in some cases, for example, if "necessary to determine the efficacy or safety of a prophylactic, diagnostic or therapeutic method."

The new proposals add the caveat that research involving placebos shouldn't proceed unless it's clear patients "will not be subject to any additional risk of serious or irreversible harm." Snaedal says the Association fears loose language could spell disaster in the third world. "If we give leeway on this issue, they will be almost allowed to do anything. Because they can say, 'at least we gave good treatment to hundreds of people'."

Williams argues widespread adoption of the Declaration could restore a measure of public confidence lost as a result of prescription drug debacles and settlements.

The American pharmaceutical industry's lobbying arm, PhRMA, lays some of the blame for that lost confidence at the feet of the media, for having sensationalized "criticisms of clinical trials."

But others argue the industry is the author of its own misfortunes and can't easily shake allegations that, like shoe and clothing companies, it is lured offshore by the equivalent of clinical "sweatshops." In the developing world, companies can take advantage of loose regulations, low costs, rubber-stamp ethics boards and easy access to desperate and often illiterate trial subjects in order to speed up the costly trial process.

"It's been said that (Big Pharma's reputation) is worse than the tobacco industry at the moment," says Dr. Michael Goodyear, an assistant professor of medicine at Dalhousie University. "It's scary stuff. I mean, no matter how much the drug industry protests and complains, they get caught out once a week doing something they shouldn't have done, because there's a lot of money involved and marketing takes precedence."